Aiysha Abid

Dr. Aiysha Abid

Sindh Institute of Urology and Transplantation, Karachi, Sindh, Pakistan
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2020 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
AKAbdul Rafay Khan
Abdul Rafay Khan
ARAli Raza
Ali Raza
SFSadaf Firasat
Sadaf Firasat
AAAiysha Abid
Aiysha Abid

1 September 2011 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Closed access
SASadia Ajaz
Sadia Ajaz
SKShagufta Khaliq
Shagufta Khaliq
AAAiysha Abid
Aiysha Abid
AHAsad Shehzad Hassan
Asad Shehzad Hassan
AHAltaf Hashmi
Altaf Hashmi
SMSyed Qasim Mehdi
Syed Qasim Mehdi
Aims: Vascular endothelial growth factor (VEGF) protein plays an important role in tumor development and progression. Polymorphisms in the VEGF gene may lead to over- or underexpression of the protein and may be associated with either risk or progression of malignancy. The aim of this case–control study is to identify and quantify the correlation between VEGF polymorphisms and renal cell carcinoma (RCC). Results: Restriction fragment length polymorphism methods were used for the analysis of VEGF polymorphisms at −2578 and +936 positions in the promoter and 3′-untranslated regions, respectively. The VEGF −2578 A-allele was associated with an increased risk of RCC (odds ratio: 1.6; 95% CI: 1.2–2.3) and A-carrier genotypes were strongly correlated (odds ratio: 2.7; 95% CI: 1.5–4.7) with higher risk. Comparison of VEGF +936 C/T polymorphism between patient and control groups revealed no association with renal carcinoma. Both VEGF −2578 C/A and VEGF +936 C/T polymorphisms showed no significant association with the histopathological parameters of RCC. Conclusions: This study shows that VEGF −2578 A-allele and A-carrier genotypes are associated with an increased risk of RCC. In groups with higher incidence of RCC, a screening test for this polymorphism may be recommended in conjunction with other established markers.

28 February 2017 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
ARAli Raza
Ali Raza
SFSadaf Firasat
Sadaf Firasat
SKShagufta Khaliq
Shagufta Khaliq
TATahir Aziz
Tahir Aziz
MMMuhammed Mubarak
Muhammed Mubarak
AAAiysha Abid
Aiysha Abid

1 September 2016 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
AAAiysha Abid
Aiysha Abid
SASadia Ajaz
Sadia Ajaz
AKAbdul Rafay Khan
Abdul Rafay Khan
FZFatima Zehra
Fatima Zehra
AHAsad Shahzad Hasan
Asad Shahzad Hasan
SKShagufta Khaliq
Shagufta Khaliq

9 October 2022 in Clinical Genetics
Verified
Journal Article
Closed access
AAAiysha Abid
Aiysha Abid
ARAli Raza
Ali Raza
AKAbdul Rafay Khan
Abdul Rafay Khan
SFSadaf Firasat
Sadaf Firasat
SSSaba Shahid
Saba Shahid
SRSyed Adib‐Ul‐Hasan Rizvi
Syed Adib‐Ul‐Hasan Rizvi

14 December 2016 in Immunological Investigations
Verified
Journal Article
Closed access
ARAli Raza
Ali Raza
SFSadaf Firasat
Sadaf Firasat
SKShagufta Khaliq
Shagufta Khaliq
AKAbdul Rafay Khan
Abdul Rafay Khan
SMShafaq Mahmood
Shafaq Mahmood
AAAiysha Abid
Aiysha Abid
Background: CCL2 is a chemoattractant for monocytes/macrophages, T cells, and natural killer cells. It is shown to be involved in the immunological responses against renal allograft. This study was conducted to access the role of urinary CCL2 expression in predicting the rejection episodes in renal transplant patients. Method: A total of 409 urine samples included in this study. The samples were consisted of (a) biopsy-proven graft rejection (n = 165); (b) non-rejection (n = 93); (c) non-biopsy stable-graft (n = 42), and (d) healthy renal donors (n = 109). The samples were quantified for the CCL2 using the MCP-1/CCL2 ELISA kit. The data were analyzed using the Statistical Package for Social Sciences (SPSS®) and MedCalc® statistical software. Results: Results showed that the CCL2 levels were significantly increased in rejection group when compared with the non-rejection, stable-graft, and control, P < 0.05. The receiver operating curve’s characteristics illustrated that the urinary CCL2 level is a good predictor for graft rejection, with an area under the curve of 0.81 ± 0.03 with optimum sensitivity and specificity of 87% and 62%, respectively, at a cut-off value of 198 pg/mL. Kaplan–Meier curve also showed better cumulative rejection-free graft survival time in group with less than 198 pg/mL of CCL2 as compared to those with expression levels of more than 198 pg/mL (30 weeks vs. 3 weeks; log-rank test, P < 0.001). Conclusion: In our study, noninvasive investigation of CCL2 levels in urine has showed potential to predict rejection episodes. It is suggested that the CCL2, with others markers, may help in early detection and monitoring of graft rejection episodes.